APLM stock icon

Apollomics
APLM

$0.2
7%
 

About: Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

Employees: 45

0
Funds holding %
of 6,689 funds
0
Analysts bullish %
of 3 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

0.44% more ownership

Funds ownership: 9.89% [Q4 2023] → 10.33% (+0.44%) [Q1 2024]

8% less funds holding

Funds holding: 13 [Q4 2023] → 12 (-1) [Q1 2024]

19% less capital invested

Capital invested by funds: $8.54M [Q4 2023] → $6.94M (-$1.6M) [Q1 2024]

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$2
895%
upside
Avg. target
$4.5
2,139%
upside
High target
$6.5
3,134%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Robert Burns
895%upside
$2
Buy
Maintained
8 May 2024
EF Hutton
Michael King
3,134%upside
$6.5
Buy
Maintained
1 Apr 2024
HC Wainwright & Co.
Robert Burns
2,388%upside
$5
Buy
Maintained
1 Apr 2024

Financial journalist opinion